Legal Representation
Attorney
Joi A. White
USPTO Deadlines
Application History
43 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Dec 2, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Dec 1, 2025 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Nov 24, 2025 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Nov 24, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Nov 10, 2025 | NOAC | E | CORRECTED NOA E-MAILED | Loading... |
| Nov 10, 2025 | DPCC | D | DIVISIONAL PROCESSING COMPLETE | Loading... |
| May 30, 2025 | DRRR | I | DIVISIONAL REQUEST RECEIVED | Loading... |
| May 30, 2025 | ERTD | I | TEAS REQUEST TO DIVIDE RECEIVED | Loading... |
| Nov 7, 2025 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| May 20, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| May 20, 2025 | EX4G | S | SOU EXTENSION 4 GRANTED | Loading... |
| May 19, 2025 | EXT4 | S | SOU EXTENSION 4 FILED | Loading... |
| May 19, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Nov 7, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Nov 7, 2024 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
| Nov 7, 2024 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
| Nov 7, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| May 15, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| May 14, 2024 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| May 14, 2024 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| May 14, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Nov 21, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Nov 17, 2023 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Nov 17, 2023 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Nov 17, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| May 30, 2023 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Apr 4, 2023 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Apr 4, 2023 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Mar 15, 2023 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Feb 25, 2023 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jan 24, 2023 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Jan 23, 2023 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jan 23, 2023 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Jul 22, 2022 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Jul 22, 2022 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Jul 22, 2022 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jul 20, 2022 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jul 13, 2022 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Jul 13, 2022 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| Jul 13, 2022 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| Nov 4, 2021 | MDSM | E | NOTICE OF DESIGN SEARCH CODE E-MAILED | Loading... |
| Nov 3, 2021 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Oct 18, 2021 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Therapeutics in the nature of cells, proteins and protein complexes for the treatment and prevention of inflammation and inflammatory diseases; biotherapeutics for the treatment and prevention of inflammation and inflammatory diseases; medicines for the treatment and prevention of inflammation and inflammatory diseases; pharmaceutical products for the treatment and prevention of inflammation and inflammatory diseases; therapeutic targets, namely, proteins or protein complexes, for the treatment and prevention of inflammation and inflammatory diseases; therapeutic cells, therapeutic proteins and therapeutic antibodies for human use for the treatment and prevention of inflammation and inflammatory diseases; therapeutics and cell therapies in the nature of cells, proteins and protein complexes for the treatment of inflammation and inflammatory diseases; engineered cell therapies in the nature of cells, proteins and protein complexes for medical purposes, namely, the treatment and prevention of inflammation and inflammatory diseases; cell platforms consisting of modified cells, cell receptors, proteins and protein complexes for the treatment and prevention of inflammation and inflammatory diseases; technology platforms for developing and engineering therapeutic cells, therapeutic proteins, therapeutic antibodies, therapeutics and cellular therapies for the treatment and prevention of inflammation and inflammatory diseases; therapeutics and cell therapies targeting targets lost in tumors for the treatment and prevention of inflammation and inflammatory diseases
Class 040
Manufacturing of cells, therapeutics and cell therapies for the treatment and prevention of inflammation and inflammatory diseases; biomanufacturing for others, namely, manufacturing of cells, therapeutics and cell therapies for the treatment and prevention of inflammation and inflammatory diseases using biological cells in the manufacturing process; custom manufacturing and engineering of biological cells, cellular targets, proteins, and antibodies for others for treatment and prevention of inflammation and inflammatory disease;
Class 042
Identification and development of therapeutic targets for others for the treatment and prevention of inflammation and inflammatory diseases; development of therapeutics and cell therapies for treatment and prevention of inflammation, and inflammatory diseases; research and development of therapeutics and cell therapies targeting targets lost in tumors for the treatment and prevention of inflammation and inflammatory diseases; biotechnology research, development, testing and analysis for the treatment of inflammation, and inflammatory diseases; providing scientific information relating to treatment and prevention of inflammation and inflammatory diseases;
Additional Information
Design Mark
The mark consists of a black square with white frame and black border containing "A2" in white text in the lower right quadrant, with the word BIO in black text appearing under the number 2 and breaking the black and white border.
Pseudo Mark
A TWO BIO
Classification
International Classes
005
040
042
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"BIO"